RESEARCH TRIANGLE PARK – Durham-based Aerie Pharmaceuticals, a developer of therapies for eye diseases, has received approval from the U.S. Food and Drug Administration (FDA) to begin selling Rocklatan, a once-daily eye drop for reducing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan is a combination of latanoprost,...
Read More
Aerie Pharmaceuticals continues expansion in Durham as it sees positive study results for its lead drug.
Read More
Aerie Pharmaceuticals saw its losses exceed expectations in the second quarter, but expects to make $20 to $30 million on its glaucoma drug in 2018.
Read More
Durham-based Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, has reported positive developments on its regulatory and financial fronts.
Read More
The $15 million the company hopes to raise will help drive the Camras Shunt through U.S. Food and Drug Administration approval and help either commercialize or sell the business.
Read More
Startup Camras Vision, which is developing a device to address glaucoma, has closed on $5.7 million in venture capital funding
Read MoreAerie Pharmaceuticals, a California-based Duke University spinoff that has research and development operations in the Triangle, has received US Food and Drug administration approval for its glaucoma drug delivered once a day via eyedrops.
Read More
